XTLbio(XTLB) - 2023 Q4 - Annual Report

Collaboration and Partnerships - XTL Biopharmaceuticals Ltd. is exploring collaboration with strategic partners for clinical trials related to hCDR1 for the treatment of Lupus disease (SLE) and Sjögren's Syndrome (SS) [4] Intellectual Property and Asset Expansion - The company is actively seeking to expand its IP portfolio by identifying additional assets [4] Financial Activities - A private placement of US$1.5 million has been approved, conditional upon the acquisition of The Social Proxy Ltd. [7]